Filtered By:
Condition: Nephritis

This page shows you your search results in order of date.

Order by Relevance | Date

Total 28 results found since Jan 2013.

New and future therapies: Changes in the therapeutic armamentarium for SLE
Best Pract Res Clin Rheumatol. 2023 Aug 24:101865. doi: 10.1016/j.berh.2023.101865. Online ahead of print.ABSTRACTFollowing better understanding of molecular pathways involved in the pathogenesis of Systemic lupus erythematosus (SLE), pharmaceutical companies have been investigating new targeted drugs for SLE. The purpose of this scoping review is to provide an updated view of the most promising targeted therapies currently in clinical development or recently approved for SLE treatment as well as of the most promising potential future therapeutic strategies in SLE. In the past several years, two new drugs have been develop...
Source: Cell Research - August 26, 2023 Category: Cytology Authors: Anca Askanase Leila Khalili Wei Tang Philippe Mertz Marc Scherlinger Eden Sebbag Fran çois Chasset Renaud Felten Laurent Arnaud Source Type: research

CRAC Channel Controls the Differentiation of Pathogenic B Cells in Lupus Nephritis
This study provides insights into the pathogenic mechanisms of LN and that CRAC channel could serve as a potential therapeutic target for LN.
Source: Frontiers in Immunology - October 22, 2021 Category: Allergy & Immunology Source Type: research

YAP1 Overexpression Is Associated with Kidney Dysfunction in Lupus Nephritis
Conclusion: YAP1 expression in the kidney tissues of LN mice was higher than that observed in normal mice, indicating that YAP1 may play an important role in the occurrence and development of LN.Pathobiology
Source: Pathobiology - August 3, 2021 Category: Pathology Source Type: research

Upregulation of FoxO3a expression through PI3K/Akt pathway attenuates the progression of lupus nephritis in MRL/lpr mice.
In conclusion, our research demonstrated that the upregulation of FoxO3a expression through inhibiting PI3K/Akt pathway attenuates murine lupus nephritis (LN). Thus, our results suggest that targeting of FoxO3a can be considered as a novel strategy for the treatment of LN. PMID: 33039957 [PubMed - as supplied by publisher]
Source: International Immunopharmacology - October 8, 2020 Category: Allergy & Immunology Authors: Zhao C, Gu Y, Chen L, Su X Tags: Int Immunopharmacol Source Type: research

(Pro)renin receptor promotes crescent formation via the ERK1/2 and Wnt/ β-catenin pathways in glomerulonephritis.
(Pro)renin receptor promotes crescent formation via the ERK1/2 and Wnt/β-catenin pathways in glomerulonephritis. Am J Physiol Renal Physiol. 2020 Aug 24;: Authors: Urushihara M, Kondo S, Kinoshita Y, Ozaki N, Jamba A, Nagai T, Fujioka K, Hattori T, Kagami S Abstract (Pro)renin receptor ((P)RR) has multiple functions, but its regulation and role in the pathogenesis in glomerulonephritis (GN) are poorly defined. The aims of this study were to determine the effects of direct renin inhibition (DRI) and demonstrate the role of (P)RR on the progression of crescentic GN. Anti-glomerular basement membrane (G...
Source: Am J Physiol Renal P... - August 23, 2020 Category: Urology & Nephrology Authors: Urushihara M, Kondo S, Kinoshita Y, Ozaki N, Jamba A, Nagai T, Fujioka K, Hattori T, Kagami S Tags: Am J Physiol Renal Physiol Source Type: research

The effect of Casitas b-lineage lymphoma b on regulating T follicular helper in lupus nephritis.
CONCLUSIONS: Cblb showed a negative regulatory effect on Tfh. The deletion of Cblb may be a key factor in progression of renal injury. PMID: 32373983 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - May 7, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Inhibition of suppressor of cytokine signaling 1 mediates the profibrotic effect of TWEAK/Fn14 signaling on kidney cells.
Abstract Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) engagement with the receptor Fn14 contributes to the fibrotic process of kidney cells in systemic lupus erythematosus. Downregulation of the protein suppressor of cytokine signaling 1 (SOCS1) correlates with amplified production of proinflammatory factors and cell apoptosis, which participate in the pathogenesis of lupus nephritis. To elucidate the potential role of SOCS1 in TWEAK/Fn14 signaling, we determined the SOCS1 levels in primary kidney cells from MRL/MpJ (control strain) or MRL/lpr (lupus-prone) mice. These cells (mesangial cells, glome...
Source: Cellular Signalling - March 22, 2020 Category: Cytology Authors: Chen J, Jia F, Ren K, Luo M, Min X, Wang P, Xiao S, Xia Y Tags: Cell Signal Source Type: research

Pim ‐1 As a Therapeutic Target in Lupus Nephritis
ConclusionThese data identify Pim ‐1 as a critical regulator of LN pathogenesis in patients with SLE. Targeting of the Pim‐1/NFATc1/NLRP3 pathway might therefore have therapeutic potential in human LN.
Source: Arthritis and Rheumatology - July 1, 2019 Category: Rheumatology Authors: Rong Fu, Yong Xia, Meirong Li, Renxiang Mao, Chaohuan Guo, Mianjing Zhou, Hechang Tan, Meiling Liu, Shuang Wang, Niansheng Yang, Jijun Zhao Tags: Original Article Source Type: research

FKN Facilitates HK-2 Cell EMT and Tubulointerstitial Lesions via the Wnt/ β-Catenin Pathway in a Murine Model of Lupus Nephritis
In this study, we therefore examined whether FKN could stimulate the process of EMT, NF-kB, TGFβ, CCL22, F4/80, inflammation, and tubulointerstitial fibrosis in a murine model of LN. We also determined whether FKN was involved in the EMT process of Wnt/β-catenin-expressing HK-2 cells. Mechanistically, we ascertained, for the first time, whether FKN up-regulated EMT-related gene signatures (e.g., vimentin, α-SMA), and hence, renal tubulointerstitial fibrogenesis, and the role of the Wnt/β-catenin signaling pathway in this process. Materials and Methods Cell Culture, Stable Infection, and Gr...
Source: Frontiers in Immunology - April 29, 2019 Category: Allergy & Immunology Source Type: research

053 Molecular mechanism of miR-145/Smad3 pathway mediated by active vitamin D in Lupus Nephritis
To elucidate the roles of 1,25(OH)2D3 and VDR in the pathogenesis of Lupus Nephritis (LN) by regulating miR-145 expression through TGF- β1-dependent Smad3 signaling pathway.From January 1, 2012 to January 1, 2017, 49 children (11 males and 38 females) with LN and 50 healthy controls were selected in this study. CD4+Tcells treated with different concentrations of 1,25(OH)2D3(1×10-6mmol/L,1×10-7mmol/L,1×10-8mmol/L).VDR-siRNA inter ference vector and human VDR overexpression vector were constructed. CD4+T cells in logarithmic growth phase were divided into 6 groups: the normal control group, the normal negative control (N...
Source: Journal of Investigative Dermatology - April 19, 2019 Category: Dermatology Authors: Y. Ding, X. He Tags: Adaptive and Auto-Immunity Source Type: research

TonEBP Suppresses the HO-1 Gene by Blocking Recruitment of Nrf2 to Its Promoter
Discussion Dynamic changes in the functional phenotype of macrophages are associated with pathogenesis of inflammatory diseases (5–7). TonEBP primes macrophages toward an M1 phenotype, which has pro-inflammatory properties. TonEBP does this by promoting expression of pro-inflammatory genes via interaction with NF-κB (36) and by binding directly to the promoter (37, 64). In addition, TonEBP suppresses expression of the anti-inflammatory cytokine IL-10 by limiting chromatin access to the promoter (37). The pro-inflammatory function of TonEBP suggests that inhibiting its expression or activation could suppres...
Source: Frontiers in Immunology - April 17, 2019 Category: Allergy & Immunology Source Type: research

NF κB and Kidney Injury
Conclusion As a critical regulator of inflammation and cell survival, the NFκB pathway is a promising target for diagnosing and treating kidney diseases. For modulation of the NFκB pathway in the clinic, a number of molecules can effectively inhibit NFκB signaling by targeting the receptors, associated adaptors, IKKs, IκBs and transcriptional regulators (144). There is further clinical evidence on small-molecule inhibitors of IKKα and NIK from recent trials on anti-cancer therapies (145). These clinical trials showed that the cancer-selective pharmacodynamic response of DTP3, the co...
Source: Frontiers in Immunology - April 15, 2019 Category: Allergy & Immunology Source Type: research

microRNA-199a may be involved in the pathogenesis of lupus nephritis via modulating the activation of NF-κB by targeting Klotho
Publication date: November 2018Source: Molecular Immunology, Volume 103Author(s): Hong Ye, Bofeng Su, Haizhen Ni, Linlin Li, Xuduan Chen, Xiaohan You, Huidi ZhangAbstractKlotho is considered to have renal protective effect by prohibiting the activation of the nuclear factor (NF)-κB pathway, while the role of microRNA-199a (miR-199a)/Klotho in lupus nephritis (LN) is still unknown. A single dose of pristane (0.5 ml) was intraperitoneally injected into 8 weeks-old female mice to establish the LN model. MiR-199a mimic or miR-199a inhibitor, Klotho plasmid or Klotho siRNA, and miR-199a inhibitor plus si-Klotho were transfec...
Source: Molecular Immunology - October 12, 2018 Category: Allergy & Immunology Source Type: research

Fra-2 is a novel candidate drug target expressed in the podocytes of lupus nephritis.
In this study, we evaluated the expression and mechanism of Fos-related antigen 2 (Fra-2) in LN. The results showed that Fra-2 was significantly increased in kidney biopsies of LN patients compared with healthy controls and other kidney disease in glomerular podocytes. The MRL/lpr mouse strain is a murine model of lupus, and it was used to study the mechanisms of Fra-2 in LN. The results showed that Fra-2 was expressed in the glomerular podocytes. We investigated the effects of inflammatory stimuli on Fra-2 protein expression in the glomerular podocytes, and found that interferon gamma was most effective at increasing Fra-...
Source: Clinical Immunology - October 5, 2018 Category: Allergy & Immunology Authors: Xu C, Miao Y, Pi Q, Zhu S, Li F Tags: Clin Immunol Source Type: research

Targeted inhibition of Axl receptor tyrosine kinase ameliorates anti-GBM-induced lupus-like nephritis.
Abstract Glomerulonephritis (GN) is a typical lesion in autoantibody and immune complex disorders, including SLE. Because the Gas6/Axl pathway has been implicated in the pathogenesis of many types of GN, targeting this pathway might ameliorate GN. Consequently, we have studied the efficacy and mechanism of R428, a potent selective Axl inhibitor, in the prevention of experimental anti-GBM nephritis. Axl upregulation was investigated with Sp1/3 siRNA in the SV40-transformed mesangial cells. For Axl inhibition, a daily dose of R428 (125 mg/kg) or vehicle was administered orally. GN was induced with anti-GBM sera. R...
Source: Journal of Autoimmunity - June 9, 2018 Category: Allergy & Immunology Authors: Zhen Y, Lee IJ, Finkelman FD, Shao WH Tags: J Autoimmun Source Type: research